A study currently underway aims to learn more about the impact of an “investigational gene therapy” for adults who have geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD). GA affects central vision and can lead to progressive, permanent vision loss. The PARASOL Geographic Atrophy Study, being conducted by Janssen Research & Development LLC, investigates the safety and efficacy of gene therapy in the treatment of GA. Study participants need to be age 60 or older and have GA caused by AMD. Additional criteria for eligibility apply as well. To learn more about the condition or details about eligibility, visit the webpage for the PARASOL Geographic Atrophy Study.
Menu
